Showing posts with label myeloma. Show all posts
Showing posts with label myeloma. Show all posts

Thursday, 18 February 2010

Dexamethasone and Lenalidomide effective together for curing multiple myeloma

Multiple myeloma, a dreaded form of cancer, can be effectively treated with a combination of dexamethasone and lenalidomide. This finding was noted in a study involving 353 patients with myeloma and conducted at 44 centers in the United States and Canada.
The study noted that multiple myeloma progression can be slowed down to a considered extent when a new thalidomide derivative is paired with a steroid. The pairing is also useful for prolonging patient life where there is a relapse after earlier treatments.
"These trials highlight how large-scale cooperation in a team effort by myeloma investigators can quickly confirm benefits and introduce new active agents for patients with this disease," Weber says. "We also owe a debt to the willing patients who participated in this study."
Multiple myeloma is caused by formation of abnormal plasma cells, a type of white blood cell, in the bone marrow. These cells multiply rapidly, crowding out normal red and white blood cells and platelets. Tumors starting in the bone marrow may cause pain, and weaken bones predisposing them to fracture. In the United States about 20,000 people are diagnosed with multiple myeloma annually, and about 11,000 succumb to the disease each year.
Thalidomide, a breakthrough drug for multiple myeloma, is produced and marketed by Celgene Corporation as Thalomid(r). The company chemically altered thalidomide to make lenalidomide, known commercially as Revlimid(r), in hopes of reducing side effects and improving efficacy against the disease. The drugs attack both the malignant cells and the cellular environment that nurtures them.
Lead author Donna Weber, M.D., associate professor in the Department of Lymphoma and Myeloma at The University of Texas M. D. Anderson Cancer Center, remarked that this combination looks effective as the complication may become immune to one therapy at times.

Wednesday, 2 September 2009

Multiple Myeloma can be treated well with Lenalidomide-dexamethasone combination

After a comprehensive study that involved 353 patients with myeloma and conducted at 44 centers in the United States and Canada, it was remarked that a combination of lenalidomide and dexamethasone can prove to be an effectual option for treating multiple myeloma.
It was found during the study that pairing a new derivative of thalidomide with a steroid can result in slowdown of the progressive nature of myeloma. It was also found that the combination of lenalidomide and dexamethasone can also help in prolonging the lives of patients who have recently relapsed from previous treatments.
From News-Medical.Net:
"These trials highlight how large-scale cooperation in a team effort by myeloma investigators can quickly confirm benefits and introduce new active agents for patients with this disease," Weber says. "We also owe a debt to the willing patients who participated in this study."
Multiple myeloma is caused by formation of abnormal plasma cells, a type of white blood cell, in the bone marrow. These cells multiply rapidly, crowding out normal red and white blood cells and platelets. Tumors starting in the bone marrow may cause pain, and weaken bones predisposing them to fracture. In the United States about 20,000 people are diagnosed with multiple myeloma annually, and about 11,000 succumb to the disease each year.
Thalidomide, a breakthrough drug for multiple myeloma, is produced and marketed by Celgene Corporation as Thalomid(r). The company chemically altered thalidomide to make lenalidomide, known commercially as Revlimid(r), in hopes of reducing side effects and improving efficacy against the disease. The drugs attack both the malignant cells and the cellular environment that nurtures them.
As per study's lead author Donna Weber, M.D., associate professor in the Department of Lymphoma and Myeloma at The University of Texas M. D. Anderson Cancer Center, a combination of drugs may become the sole option when a disease becomes resistant to one therapy.

Monday, 17 August 2009

Low doses of Steroids prove effective for multiple myeloma


Lenalidomide plus low-dose dexamethasone therapy can prove to be more effective than lenalidomide plus high-dose dexamethasone for treating multiple myeloma, according to findings reported by S. Vincent Rajkumar, M.D. at the American Society of Hematology's annual meeting.

These findings were part of results of the Eastern Cooperative Oncology Group Phase III clinical trial E4A03.

Dr. Rajkumar, Mayo Clinic Cancer Center hematologist and lead investigator of the study, remarked that he was quite surprised at first to know that high doses of steroids can lead to minimized survival rates besides increasing the risk of side effects.

It will be important to note here that lenalidomide and high-dose dexamethasone, which is referred to as Rev/Dex, is presently used as a second-line treatment for myeloma.

From News-Medical.Net:
“The standard treatment for myeloma usually includes high doses of steroids such as dexamethasone. In this study we were hoping to find that a lower dose of steroids would be just as effective,” says Dr. Rajkumar, Mayo Clinic Cancer Center hematologist and lead investigator of the study. “We were surprised to find that the regimen with high-dose steroids actually was decreasing survival, besides contributing to increased side effects.”

The study compared combination treatment of oral medications lenalidomide (a novel chemotherapeutic agent) and either high- or low-dose dexamethasone (a potent steroid effective against myeloma) in 445 patients with newly diagnosed myeloma. Lenalidomide plus high-dose dexamethasone had an 18-month survival rate of 80 percent. The comparative therapy using low-dose dexamethasone showed a significantly higher 91 percent overall survival rate at 18 months, with much less toxicity.

“The lower survival rates with the high-dose dexamethasone can be attributed to disease progression as well as treatment-related toxicities,” says Dr. Rajkumar. “This is a major advance in the treatment of this cancer, and also gives researchers a new direction to explore -- that more is not necessarily better.”
The findings of this reported study are expected to offer a new paradigm before scientists who have been making every possible effort to help patients with multiple myeloma.